Christopher Morris, MD Professor, Pediatrics School of Medicine

Research & Grantsmanship 

  Funded Research Project (PI)

• Prophylaxis Against Regimen Related Toxicity Following Bone Marrow Transplantation With Continuous Infusion Antithrombin-III ( 1/1996 - 1/1997 )

• Red Cell Adhesion of Sickle and Polycythemia Vera Blood ( 1/1987 - 1/1992 )

• CYCLOPHOSPHAMIDE ETOPOSIDE AND FRACTIONATED TOTAL BODY IRRADIATION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH LEUKEMIA, MYELODYSPLASIA, OR LYMPHOMA ( 4/2003 - Present )

• BUSULFAN, CYCLOPHOSPHAMIDE, AND ETOPOSIDE AS CONDITIONING THERAPY FOR STEM CELL TRANSPLANTATION FOR PATIENTS WITH LEUKEMIA ( 10/2002 - Present )

• UARK 2000-44, A RANDOMIZED TRIAL OF ANTI-CD25 MoAb IN REDUCING THE INCIDENCE OF SEVERE GRAFT-VERSUS-HOST-DISEASE (GVHD) IN PATIENTS WITH HIGH-RISK HEMATOLOGICAL MALIGNANCIES RECEIVING DELAYED GVHD PROPHYLAXIS ( 1/2000 - Present )

  Funded Research Project (CI)

• Endothelial cell adhesion molecule expression in response to thrombin stimulation or anti-thrombin III deficiency ( 1/1998 - 1/1999 )

  Abstracts Reporting Research -- Non-Peer Reviewed

• FACT Program Director - After several years performing pediatric blood and and marrow transplants, the program reached the required number of transplants within the required time frame and established a documented standardized methodology for blood and marrow transplant. Accreditation of the program was granted by the Foundation for Hematopoietic Cell Therapy (FACT) in May 2007. ( 5/2007 - Present )

• Program Director Blood and Marrow Transplant - I was recruited to Loma Linda in 2002 to develop and administer a program for blood and marrow transplant. This included development of a new pediatric transplant program and administration of a small adult transplant program. ( 5/2002 - Present )